|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 7. Transgenic analysis of the role of the Tcf/Lef and Gli binding sites
present in the epaxial enhancer of the Myf5 gene. (A-E)
X-gal staining of whole-mount embryos at E9.5, with the following enhancer
sequences upstream of the ß-globin promoter and the nlacZ
reporter transgene: (A) the early epaxial enhancer (Ep), (B) the extended
version of this enhancer (EpE), (C) the Ep enhancer with a 5' and
3' end deletion that removes the TBF4 and TBF5 Tcf/Lef binding sites
(
Ep), (D) the deleted Ep enhancer with the Gli site mutated
(EpGm), and (E) the deleted Ep enhancer with the Gli and
remaining non-consensus Tcf/Lef binding site mutated (EpGT/Lm).
(F,H) Transverse sections of the embryo shown in A at two
different levels in the interlimb region, showing extensive labelling of cells
in the epithelial dermomyotome of somites. (G,I) Transverse
sections of the embryo shown in B at two different levels in the interlimb
region; labelled cells are restricted to the epaxial region of the
dermomyotome, closest to the neural tube (NT). The number of somites (S) is
indicated. (J) Schematic representation of the fragments of the epaxial
enhancer used in the different transgenic constructs shown in A to I. EpE
corresponds to the EpExt sequence and Ep to the 5 sequence
presented in Fig. 6B. Red
circles indicate the positions of the Tcf/Lef binding sites, the green
rectangle indicates the position of the Gli binding site and the blue circle
indicates the non-consensus Tcf/Lef binding site. White crosses indicate that
the corresponding sites have been mutated.
|
